The NOAR Europe brings together an international and interdisciplinary community dedicated to advancing astatine-211–based radiopharmaceuticals and targeted alpha therapy. Over the past years, NOAR has demonstrated the strength of collaborative research across radiochemistry, preclinical development, clinical translation, and regulatory science. The conference aims to build on this momentum by providing a focused platform for scientific exchange, discussion, and strategic alignment.